Graft function · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Graft infection · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
Risk of receiving any allogeneic blood product (data only available for intraoperative blood product use) · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Tranexamic acid changes risk of receiving any allogeneic blood product (data only available… compared with placebo (very low certainty).
1 finding from 1 review
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Tranexamic acid changes risk of reoperation or repeat procedure for bleeding within 7 days compared with placebo (very low certainty).
1 finding from 1 review
Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery
Summary of findings: Tranexamic acid showed no clear difference in risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with placebo (low certainty).
1 finding from 1 review
All‐cause infant mortality at longest · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of infants with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of infants with HBV mother‐to‐child transmission · HIV‐positive pregnant women co‐infected with hepatitis B virus
1 finding from 1 review
Maternal death · HIV‐positive pregnant women co‐infected with hepatitis B virus
1 finding from 1 review
Proportion of mothers with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found